It will be interesting to see what they come up with in the next trial results. I think at that point they will know what they have.
Agree. My own observation is that they are simply trying to cast too wide of a net for the first product. I acknowledge that it's a very "entrepreneurial" move to do so, and its clear they are ambitious about the product's potential. The only upside is this Severe trial; it may give them the data they need to clearly define a "1-dose patient."
I think it's important for the placebo data to look like placebo data. All it takes is one weird improver from the group of six to raise huge questions.
Agree completely. In complete Diesel Theory, isolating the Severe Phase 1B to a homogeneous group with established hearing loss, should minimize the placebo effect.
Let's hope that research into long-term COVID-19 symptoms will accelerate research into tinnitus treatments. We as a community of tinnitus sufferers might not be billionaires, but the biotech companies addressing the issue certainly will be if they get their products out there soon enough to capture the wave of new people with tinnitus. This may be a COVID-19-blessing-in-disguise, i.e. hearing issues appear to be a potential outcome of covid infection, so it seems very likely that there will be a faster pace of research and development of treatments relevant to our community than there was before the pandemic:
I believe they were referring to hospitalized patients so that number would be much smaller. It still highlights the issue, though.
I don't disagree but thought it was an interesting switch of focus even if usually meaningless.
Sure, there can be something more going on but you can't say the drug doesn't work.
I should have clarified what I meant by "it doesn't work" and probably should not have used that wording.
It wouldn't surprise me if they wait until they comment on the Phase 2A results (assuming they do). Assuming the ARHL Phase 1B looks like the other Phase 1s, they can cushion a second fallout from whatever confusion comes from the Phase 2A full readout.
And what about the T and the lost frequencies between 16 kHz and 20 kHz? I am only 26 and lost most of it in an acustic trauma 4 months ago. I wonder why I had this good hearing until now but it feels so wrong now.
Good news, right? They are doing this after getting age-related hearing loss data.
Sorry to hear about your tinnitus and how long you have suffered at its malicious hands.
It's hard to say with trademarks and patents. It shows they're still focused on getting it to product, and know they need a name that is marketable to doctors and patients that is memorable. Filing for trademarks isn't really all that expensive in the grand scheme of things, but it's likely there's other marketing work going on alongside this filing that is (think commercials, print advertisements, website updates, other creative work).Good news, right? They are doing this after getting age-related hearing loss data.
I liked FX-322 though
TBH, it probably doesn't mean much in relation to the trials. Think of it like getting a reservation for a name they might use.
If they're just going to misspell "acoustic" they might as well go full metal and put some random umlauts over the vowels.
We're just used to it. Honestly it sounds a bit Marvin the Martian, if you think about it.I liked FX-322 though
True, to be honest I don't care if it's called "Ass Blaster 5000," I'm still taking it with a smile.
Member
